Today before the opening bell, Rainbow Coral Corp. announced that it is making plans to empower patients to demand better care through both innovation and education as the company sets its sights on the fast-growing, $232 billion personalized medicine market.
By delivering new technologies in the sectors of the personalized medicine field expected to see the most growth, Rainbow Coral hopes to arm patients with more effective and efficient treatment options than ever before. But, according to today's press release, bringing new ideas and products to the marketplace is only one piece of the company's expansion strategy.
"Our ultimate goal is to help spur patient-driven demand for personalized medicine," RBCC CEO Patrick Brown stated. "That requires not just delivering new innovations, but helping to educate patients on these promising new treatment options. That's why we're developing a comprehensive media and marketing strategy."
PricewaterhouseCoopers projects that the personalized medicine market in the U.S. could grow to as much as $452 billion by 2015. One of the fastest-growing fields in the market is companion diagnostics, an area of RBCC's focus, which could grow to as large as $42 billion by 2015, according to industry analysts TriMarkPublications.com.
For more information, visit rainbowbiosciences.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net